Loading current stock analysis…
Loading current stock analysis…
As of 2026-08-25
For the quarter ended June 30, 2026 (Q1 FY2026-27), Cipla reported Revenue from Operations of ₹7,119.28 crore. Profit Before Tax was ₹1,081.93 crore, and Profit/Loss for the period was ₹785.55 crore. The company's Net Profit Margin was 11.08% and its EBITDA Margin was 19.71%.
Comparing Q1 FY2026-27 to Q1 FY2025-26, Revenue from Operations increased from ₹6,957.47 crore to ₹7,119.28 crore. Profit Before Tax decreased from ₹1,769.93 crore to ₹1,081.93 crore, and Profit/Loss for the period decreased from ₹1,291.61 crore to ₹785.55 crore.
On July 28, 2026, Cipla experienced an upward gap, opening materially above the previous close. On July 23, 2026, there was an unusually active downward session with trading activity substantially higher than usual and the price closing lower. On July 22, 2026, a downside gap occurred, with the session opening materially below the previous close.
On a daily timeframe, Cipla is in a weak downtrend, with the price below the 20-day Simple Moving Average (SMA). However, on a weekly timeframe, the trend is a weak uptrend, with the price above the 20-day SMA. The current price risk is assessed as 'contained', with recent drawdown and price variability within thresholds.
Cipla filed a shareholding pattern disclosure on August 21, 2026, for the period ending March 31, 2026, showing promoter and promoter group shareholding at 29.21% and public shareholding at 70.79%. Additionally, on August 19, 2026, the company announced receipt of an order from the National Company Law Tribunal (NCLT), Mumbai Bench, regarding the amalgamation of Inzpera Healthsciences Limited with Cipla.
Showing 3 of 18 candles
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Trading activity was substantially higher than usual and the price closed lower.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹7,119.28 crore | ₹6,541.20 crore | ₹7,074.48 crore | PEAK₹7,589.44 crore | ₹6,957.47 crore |
| Profit Before Tax | ₹1,081.93 crore | ₹707.06 crore | ₹893.11 crore | PEAK₹1,853.53 crore | ₹1,769.93 crore |
| Profit Loss For Period | ₹785.55 crore | ₹542.51 crore | ₹674.25 crore | PEAK₹1,353.37 crore | ₹1,291.61 crore |
| Comprehensive Income For The Period | ₹979.61 crore | ₹678.30 crore | ₹878.36 crore | PEAK₹1,619.80 crore | ₹1,373.02 crore |
| Tax Expense | ₹294.83 crore | ₹156.95 crore | ₹218.55 crore | PEAK₹500.46 crore | ₹477.88 crore |
| Other Comprehensive Income | ₹194.06 crore | ₹135.79 crore | ₹204.11 crore | PEAK₹266.43 crore | ₹81.41 crore |
Cipla reported a 2.3% increase in revenue from operations to ₹7,119 crore for the quarter ended 30 June 2026. However, profit before tax declined 38.9% to ₹1,082 crore as expenses rose faster than sales. Net profit fell 39.2% and earnings per share dropped to ₹9.77 from ₹16.07 a year ago.
Revenue from operations was ₹7,119 crore in Q1 FY2026-27, compared with ₹6,957 crore in the same quarter last year – a 2.3% increase. Sequentially, revenue recovered by 8.8% from the March 2026 quarter (₹6,541 crore). Other income was ₹210.9 crore for the quarter.
Profit before tax stood at ₹1,082 crore, down sharply from ₹1,770 crore in Q1 FY2025-26. The effective tax rate remained roughly stable at about 27%, leading to a tax charge of ₹295 crore (previous year: ₹478 crore). Profit for the period totalled ₹785.55 crore, a decline of 39.2% from ₹1,291.61 crore. Basic earnings per share fell to ₹9.77 from ₹16.07.
The drop in profit against only modest revenue growth was driven by costs that increased at a faster pace. Several large expense lines contributed to the cost base in the quarter:
While year-on-year comparisons for cost of materials, employee benefits, and depreciation are not available in the supplied figures, other expenses grew at nearly double the pace of revenue, and finance costs also increased. The combination of still-high absolute cost levels and only a small revenue gain compressed profit before tax by 38.9%.
Achin Gupta, MD and Global CEO of Cipla, stated: "We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of INR 7,119 Cr. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of Consumer Health Business maintained leadership position. The US business posted a revenue of $ 162 Mn during the quarter. We expect continued sequential growth in North America, supported by upcoming product pipeline. South Africa private business continued to grow faster than the market. Emerging Markets and Europe continued its growth trajectory with revenue growth of 5% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front."
Cipla’s first quarter shows a clear gap between steady, low-single-digit revenue growth and a severe profitability squeeze. Revenue edged up 2.3%, but rising costs – especially the 3.9% rise in other expenses and higher finance costs – pushed profit before tax down by nearly 39% year-on-year. Earnings per share fell from ₹16.07 to ₹9.77. While revenue improved sequentially from the March 2026 quarter, the year-on-year profit decline remains the dominant feature of these results.
Exchange disclosures and regulatory announcements for Cipla.
On August 25, 2026, Cipla Ltd. notified stock exchanges that the USFDA conducted a follow-up cGMP inspection at its Pithampur, India manufacturing facility from August 17 to August 25, 2026. The inspection concluded with the issuance of seven Form 483 observations, prompting the company to commit to addressing these findings comprehensively within stipulated timeframes.
As of March 31, 2026, Cipla Limited reported promoter and promoter group shareholding at 29.21% (235,287,003 voting rights), while public shareholding stood at 70.79%. Key individual shareholders included Sophie Ahmed with 57,100,000 shares (0.0571%) and Yusuf Khwaja Hameid with 150,521,183 shares (0.1869%). Institutional holdings were led by Foreign Portfolio Investors Category One at 21.84%, Mutual Funds at 18.66%, and Insurance Companies at 11.24%, with LICI New Endowment Plus-Secured Fund holding the largest single insurance stake at 0.0962%.
The National Company Law Tribunal (NCLT), Mumbai Bench, on August 18, 2026, allowed the Scheme of Amalgamation of Inzpera Healthsciences Limited (wholly-owned subsidiary) with Cipla Limited, with an appointed date of April 1, 2026. Since Inzpera is a wholly-owned subsidiary, all its equity shares held by Cipla will be cancelled, and no new shares will be issued. The NCLT dispensed with meetings of Cipla's shareholders and creditors but directed Cipla to issue notices to them and to various regulatory authorities, allowing 30 days for objections.
On August 11, 2026, Cipla Ltd. disclosed updated ESG ratings for FY 2025-26 from SES ESG Research and NSE Sustainability Ratings & Analytics, with SES assigning a Grade B rating of 69.9 (up from 69.3) and NSE assigning an Aspiring rating of 67 (down from 69). The company attributed the decline in the NSE rating to a product recall by its wholly owned subsidiary, Cipla USA Inc., which occurred in January 2026.
Cipla Limited announced on August 4, 2026, that its wholly-owned subsidiary, InvaGen Pharmaceuticals, Inc., has received the Establishment Inspection Report (EIR) from the USFDA for its Hauppauge, New York manufacturing facility. This report indicates the closure of the Pre-Approval Inspection (PAI) previously conducted by the USFDA.
On July 31, 2026, Cipla Limited's Operations and Administrative Committee allotted 7,850 fully paid-up equity shares of INR 2 each. This allotment was pursuant to the exercise of employee stock options and stock appreciation rights under the ESOS 2013-A and Cipla ESAR Scheme 2021. The total number of shares increased by 7,850, and the paid-up share capital increased by INR 15,700.
On July 31, 2026, Cipla Limited allotted 7,850 equity shares of INR 2 each under its ESOS 2013-A and Cipla ESAR Scheme 2021. This allotment increases the company's issued, subscribed, and paid-up share capital to INR 1,61,57,06,332, representing 80,78,53,166 equity shares.
Cipla Limited reported its Q1 FY27 earnings, achieving the highest ever Q1 revenue of INR 7,100 crores, a 2% year-on-year growth. The company's One India business saw its highest quarterly revenue with 12% year-on-year growth, driven by its branded prescription business. North America generated $162 million in quarterly revenue, with the successful launch of generic Ventolin in the U.S. The U.S. FDA completed routine inspections of Cipla's Verna, Goa facility (classified VAI) and its Invagen facility in New York (with one Form 483 observation).
Cipla Limited has received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in three strengths: 100/50 mcg, 250/50 mcg, and 500/50 mcg. This product is a therapeutically equivalent version of Advair Diskus®, used for asthma and COPD. The U.S. market for this product is approximately $908 million. The launch in the United States is expected in Q2 of FY 2026-27. This marks Cipla's first dry powder inhaler (DPI) approval from its U.S.-based manufacturing network.
Cipla Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, on July 24, 2026. The Board of Directors approved these results on July 23, 2026. The results are available on the company's website and the websites of BSE Limited and the National Stock Exchange of India Limited.
Cipla Limited has made the audio recording of its earnings conference call for the quarter ended June 30, 2026, available on its website. This disclosure was made on July 23, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Cipla Limited announced its investor presentation for July 23, 2026, reporting a highest-ever quarterly revenue of INR 7,119 Cr for Q1FY27. The company also reported Profit After Tax (PAT) of INR 789 Cr and highlighted growth in various segments including North America, One Africa, and Emerging Markets & Europe. Key product launches and market performance in India, South Africa, and the US were detailed, alongside progress on ESG goals.
Cipla Limited's Board of Directors approved a change in reporting for Mr. Sanjay Joseph, Head of API Business, on July 23, 2026. Consequently, Mr. Joseph will cease to be Senior Managerial Personnel effective July 24, 2026.
Cipla Limited's Board of Directors approved a change in its Chief Financial Officer role on July 23, 2026. Ashish Adukia transitioned from Global Chief Financial Officer to an internal business leadership role, ceasing his KMP position effective close of business hours on July 23, 2026. Dinesh Jain was appointed as the new Global Chief Financial Officer and KMP, effective July 24, 2026.
Cipla Limited's Board of Directors approved changes to Key Managerial Personnel (KMPs) and officers authorized under SEBI Listing Regulations on July 23, 2026. These changes are effective July 24, 2026, and include Mr. Achin Gupta as Managing Director and Global Chief Executive Officer, Mr. Dinesh Jain as Global Chief Financial Officer, Mr. Rajendra Chopra as Company Secretary and Compliance Officer, and Ms. Meera Vanjari as Chief General Counsel (Global).
Cipla Limited granted 5,530 stock options under ESOS 2013-A with a 2-year vesting period and 5-year exercise period from vesting, and 19,179 Employee Stock Appreciation Rights (ESARs) under ESAR 2021 with 3-year graded vesting and a 5-year exercise period from vesting. The exercise price for both is INR 2 per option/share. These grants were made on July 23, 2026.
Cipla Limited has disclosed an audio recording of a call held on July 23, 2026. The recording was uploaded to the company's website on July 23, 2026, at 19:12:00. Prior intimation of this earnings call was provided to the exchange on July 8, 2026.
Cipla Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, on July 23, 2026. The company reported consolidated revenue from operations of ₹7,119.28 Crores and a net profit after tax of ₹785.55 Crores for the quarter. The filing also detailed ongoing litigation with the National Pharmaceutical Pricing Authority regarding alleged overcharges, with the total amount covered by notices aggregating to ₹2,011 Crores. Additionally, an exceptional item of ₹275.91 Crores was recognized due to changes in labor laws impacting gratuity and leave liabilities.
Cipla Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026, reporting global revenues of INR 7,119 Cr. The One India business achieved its highest quarterly sales with 12% YoY growth. North America generated $162 Mn in revenue, while Emerging Markets and Europe saw a 5% YoY growth in USD terms. R&D investments were INR 486 Cr, and the company maintained a net cash position of INR 9,494 Cr.
Cipla Limited's Board of Directors, in a meeting on July 23, 2026, approved the appointment of Dinesh Jain as Chief Financial Officer and Key Managerial Personnel, effective July 24, 2026, with a term of 14 months. Concurrently, Ashish Adukia ceased to be Global Chief Financial Officer and Key Managerial Personnel effective July 23, 2026, transitioning to an internal business leadership role. Sanjay Joseph also ceased to be Senior Management Personnel effective July 24, 2026, due to a change in reporting structure.
Cipla Limited reported that its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Central Islip, New York, underwent a routine USFDA current Good Manufacturing Practices (cGMP) inspection from July 13-17, 2026. The inspection concluded with one observation documented on Form 483, which Cipla Limited will address with the USFDA.
Cipla Limited submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The certificate, received from Registrar and Share Transfer Agent KFin Technologies Limited, confirms that during the period April 1, 2026, to June 30, 2026, dematerialization requests were processed within 15 days of receipt. This included confirming, listing, and cancelling security certificates, and updating the register of members.
Cipla Limited submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The certificate, received from Registrar and Share Transfer Agent KFin Technologies Limited, confirms that during the period April 1, 2026, to June 30, 2026, dematerialization requests were processed within 15 days of receipt. This included confirming, listing, and cancelling security certificates, and updating the register of members.
Cipla Limited received an ESG rating from Crisil ESG Ratings & Analytics Limited on July 11, 2026. The company was assigned a 'Crisil ESG 69' and a 'Crisil Core ESG 66' rating.
Cipla Limited will release its unaudited Q1FY27 financial results on July 23, 2026. The company will host an earnings conference call on the same day at 1600 hrs IST to discuss financial performance and answer questions. A transcript will be available on the company's website.
Recent market and company developments associated with Cipla.
From Cipla receiving seven observations from the US Food and Drug Administration to Varun Beverages plans to enter the alcoholic beverages business; these are stocks to track ahead of Wednesday trading session.
The Indian stock market is set to open lower due to weak global cues. The Nifty 50 fell to 24,219.05, while the Sensex declined 171.72 points. The escalating US-Iran tensions and new sanctions could affect market sentiment and energy prices.
Indian stock markets are anticipated to open flat amidst weak global cues, following a steep decline in the previous session. Brent crude prices rose amid supply concerns, while global financial markets remain risk-averse due to the US-Iran standoff and its impact on energy supplies.
Stock Market Live Updates: We are in the second half of the day's trade, and the markets are looking to mark a recovery from the day's low. The markets are under pressure, as indices trade lower at the beginning of a new week. The Nifty is down nearly 80 points, falling below the 24,300 mark. Infosys, Tata Motors PV and HCLtech are top losers.
India Inc's Q1 performance shows strong revenue growth, defying initial gloom, despite challenges from rising input costs.
2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decades of growth from importing medicines to global leadership. The nation now supplies a significant portion of the world's generic medicines and vaccines. The Covid-19 pandemic further showcased the industry's manufacturing capabilities globally. Government initiatives now aim to foster innovation and high-value biopharmaceutical production.
The approval is for Cipla's US manufacturing facility—a significant positive at a time when US-based production is gaining strategic importance amid the Trump administration's tariff push and increasing scrutiny of overseas generic drug manufacturing.
Global semiconductor sell-off drags markets down, while Indian IT stocks like TCS and Infosys show resilience amid the trend.
Dalal Street is expected to open on a cautious note after Monday's rebound, as traders balance lower crude oil prices and a pause in Middle East tens
Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw significant drops in their net profits and operating margins. However, their domestic businesses continued to perform well, offering a positive outlook. Obesity therapies and specialty product launches are expected to drive future growth for these companies. Analysts have consequently reduced earnings forecasts for the upcoming fiscal years.
From local outsourcing and tech transfers to passing costs on to American consumers, pharmaceutical firms are weighing tactical options to protect their margins.
Discover why Bandhan Large & Mid Cap Fund earned a 5-star rating. Analysis of long-term SIP returns, risk ratios, portfolio shifts, and investment strategy.
Q1 Results Today, 25th July 2026 Live Updates: Track all the latest Q1 FY27 earnings announcements, corporate developments and management commentary as companies report their June quarter results.
Sensex, Nifty, Share Prices Live Updates: Rising crude oil prices, unwinding of yen trade, fresh US tariffs, weakening rupee hurts market sentiment
Q1 Results LIVE Updates: SBI Life, Shriram Finance Tata Consumer Products, NTPC, ACC, Atul, Bank of Baroda, Apar Industries, CG Power, CreditAccess Grameen, CONCOR, DCB Bank, Dalmia Bharat, Greenply Industries, Jindal Steel, Dr Lal Pathplabs, Kfin Tech, New India Assurance, Laurus Labs, Ramkrishna Forgings, Sapphire Foods, Shakti Pumps, SBI Cards, Sterlite Tech, V-Mart, Welspun Corp, are among the companies reporting their Q1 results today. Also watch for earnings reactions from Infosys, IndiGo and others. Stay tuned for all the LIVE earnings updates.
New Delhi: The proposed steep tariffs announced by the US on generic medicines could significantly affect India’s largest pharmaceutical export market, economic think tank GTRI said on Wednesday. However, it said that the impact is unlikely to be uniform. Also Read Mcap of nine of top-10 most valued firms erodes by Rs 2.74 lakh cr; […]
Comprehensive Section Breakdown for Cipla
Strategic Vision: Develops, manufactures, and commercializes pharmaceutical products globally.
Category: Manufacturing
Manufactures tablets, capsules, injectables, and liquid medicines covering cardiovascular, chronic kidney disease, neuropsychiatry, and anti-infective segments.
Category: Manufacturing
Develops and produces aerosols, sprays, dry powder inhalers (Revolizer), and metered-dose inhalers (Synchrobreath) for asthma and COPD therapies.
Key Products & Services: Revolizer • Synchrobreath
Category: Manufacturing
Synthesizes bulk chemical actives, custom synthesis compounds, and specialty pharmaceutical intermediates for internal formulation and export.
Core Thesis: Cipla operates a vertically integrated business model focusing on complex drug development, device engineering, and digital care platforms.
• Upstream API and Formulation Sourcing: Cipla maintains raw material security by manufacturing critical chronic care APIs in-house, reducing dependency on external chemical brokers and securing the supply chain. • Integrated Device-Formulation Engineering: Co-develops drug formulations alongside proprietary delivery hardware to ensure consistent dosage delivery. • "One India" Market Integration: Integrates prescription medicines with consumer health products via its subsidiary, Cipla Health Limited, cross-promoting OTC wellness products through trade distributors. • Breathefree Patient Care Ecosystem: Integrates product sales with patient diagnostic and support networks, linking screening centers with digital smart inhalers.
• Vertically integrated business model
• Focus on complex drug development and device engineering
• In-house manufacturing of critical APIs
• Co-development of drug formulations and proprietary delivery hardware
• Integrated patient care ecosystem